Last reviewed · How we verify
Homeopathy 1
Homeopathy 1 is a Small molecule drug developed by Shaare Zedek Medical Center. It is currently in Phase 3 development.
Homeopathy 1 is a homeopathic preparation that operates on principles of extreme dilution and potentization, theoretically stimulating the body's innate healing response.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Homeopathy 1 |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Homeopathic remedies are prepared through serial dilution and succussion (vigorous shaking) of active substances, often to the point where no molecular traces remain. The proposed mechanism suggests that the preparation carries an 'energetic imprint' that triggers the body's self-healing mechanisms, though this mechanism lacks conventional pharmacological validation.
Approved indications
Common side effects
Key clinical trials
- Flourish Vaginal Care System to Establish Neovaginal Microbiome (NA)
- Effects of Flourish HEC and BioGenesis to Improve Conception (PHASE1)
- A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation (PHASE4)
- Individualized Homeopathy to Reduce the Use of Antibiotics in Women With Recurrent Uncomplicated Urinary Tract Infections (PHASE4)
- A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD (PHASE2)
- Flourish HEC to Prevent Recurrence of BV (NA)
- Effects of Flourish on Recurrent Urinary Tract Infection (NA)
- Effects of Flourish HEC on Localized Provoked Vulvodynia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Homeopathy 1 CI brief — competitive landscape report
- Homeopathy 1 updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI
Frequently asked questions about Homeopathy 1
What is Homeopathy 1?
How does Homeopathy 1 work?
Who makes Homeopathy 1?
What development phase is Homeopathy 1 in?
Related
- Manufacturer: Shaare Zedek Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing